Most people think of aging as something that happens gradually and inevitably — cells wear out, organs slow down, and the body loses its capacity to recover as quickly as it once did. What is less understood is that much of this decline is not simply the passage of time. A significant portion of biological aging is driven by a specific, measurable process called inflammaging — and understanding it changes how you think about what is and is not within your control.
What is inflammaging?
Inflammaging is chronic, low-grade inflammation that develops with age and persists without any obvious infection or injury to trigger it. Unlike the acute inflammation you feel after a sprained ankle — which is sharp, localised, and resolves — inflammaging is silent. It runs continuously in the background, produces no dramatic symptoms, and yet causes cumulative damage to tissues, organs, and systems throughout the body over years and decades.
The term was coined by Italian researcher Claudio Franceschi, whose landmark work established inflammaging as a central mechanism in biological aging — not just a byproduct of it. The distinction matters: inflammaging is not something that happens because you are getting older. In many respects, inflammaging is what makes you get older, biologically speaking.
What causes it?
Several interconnected processes drive inflammaging, and they tend to reinforce each other over time.
- Cellular senescence. As cells age, some stop dividing but do not die. These senescent cells accumulate in tissues and release a cocktail of inflammatory signals — a pattern called the senescence-associated secretory phenotype, or SASP. The longer these cells sit in the body, the more inflammatory noise they generate.
- Immune system drift. The immune system becomes less precise with age. It loses some of its ability to distinguish genuine threats from harmless signals, leading to a state of low-level activation that does not fully switch off. This is closely linked to a parallel process called immunosenescence — the gradual erosion of immune function that leaves older people both more inflamed and less effectively protected.
- Mitochondrial dysfunction. Mitochondria — the energy-producing structures inside cells — generate inflammatory signals when they malfunction. As mitochondrial quality declines with age, the volume of these signals increases.
- Gut microbiome changes. The composition of gut bacteria shifts with age in ways that favour pro-inflammatory species. Since the gut is one of the largest interfaces between the body and the external environment, these changes have systemic effects on inflammation levels throughout the body.
None of these causes is entirely independent. They interact, amplify each other, and over time create a self-reinforcing inflammatory state that accelerates across multiple body systems simultaneously.
What does inflammaging actually do to your body?
This is where the clinical significance becomes concrete. Inflammaging is not a theoretical construct — it is directly linked to most of the major chronic conditions associated with aging.
Cardiovascular disease
Chronic low-grade inflammation drives the development and progression of atherosclerosis — the buildup of plaque in arterial walls. Elevated inflammatory markers are among the strongest predictors of cardiovascular events, independent of cholesterol levels.
Cognitive decline and neurodegeneration
Neuroinflammation — inflammation within the brain — is implicated in Alzheimer’s disease, Parkinson’s disease, and general age-related cognitive decline. The same inflammatory cytokines circulating in the blood can cross into the brain and activate microglial cells, the brain’s resident immune cells, in ways that damage neural tissue over time.
Joint degeneration
Osteoarthritis is not simply a mechanical wear problem. Inflammaging creates the joint environment in which cartilage breakdown accelerates — which is why people with systemic inflammatory conditions age their joints faster, and why patients with osteoarthritis have measurably higher rates of cardiovascular disease than the general population.
Metabolic dysfunction.
Chronic inflammation impairs insulin signalling, promotes fat storage in the wrong places, and contributes to the development of type 2 diabetes and metabolic syndrome — conditions that then generate further inflammation in a self-perpetuating cycle.
Muscle loss
Sarcopenia — the progressive loss of muscle mass and strength with age — is partly driven by the inflammatory environment. Pro-inflammatory cytokines interfere with muscle protein synthesis and accelerate muscle fiber breakdown.
The pattern across all of these is consistent: inflammaging does not cause one disease. It creates the biological conditions in which many diseases become more likely simultaneously.
Can you measure it?
Yes, to a degree. Several blood markers reflect the level of systemic inflammation in the body. C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α) are the most commonly measured. Elevated levels of these markers — even within ranges considered clinically normal — are associated with accelerated biological aging and higher disease risk.
This is why measuring inflammatory markers is increasingly part of advanced health assessments aimed at biological age rather than just disease diagnosis. A 45-year-old with chronically elevated IL-6 and CRP may be biologically older than their birth certificate suggests — and more vulnerable to the conditions that typically appear a decade later.
What can be done about inflammaging?
Lifestyle interventions have a real and measurable effect. Regular physical activity consistently reduces inflammatory markers, as does a diet low in processed foods and refined sugars, adequate sleep, and stress management. These are not trivial — the evidence supporting their role in reducing inflammaging is substantial and should not be overlooked in favour of any clinical intervention.
Where lifestyle alone reaches its limits — particularly in patients with already elevated inflammatory burden, existing joint or metabolic disease, or those who have optimised their lifestyle and are still showing signs of accelerated aging — biological interventions become relevant.
UC-MSC therapy works directly on the mechanisms that drive inflammaging. UC-MSCs suppress the overactive cytokine signalling that characterises chronic low-grade inflammation, modulate the immune response that has lost its ability to self-regulate, and create conditions that support cellular repair rather than ongoing damage. This is not a general wellness claim — it reflects the documented paracrine mechanism through which UC-MSCs act in the body, and the clinical evidence supporting their anti-inflammatory effects across multiple conditions.
For patients who are managing the early effects of inflammaging — progressive joint degeneration, declining energy and recovery, early metabolic changes, or elevated inflammatory markers without a clear diagnosis — UC-MSC IV therapy offers a systemic intervention that addresses the inflammatory environment itself, rather than any single downstream symptom.
About EDNA Wellness
EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).
All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.
For more information or to book a consultation
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
References
- Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. 2018;14(10):576–590. https://pubmed.ncbi.nlm.nih.gov/30046148/
- Aranda JF, Ramírez CM, Mittelbrunn M. Inflammageing, a targetable pathway for preventing cardiovascular diseases. Cardiovascular Research. 2025;121(10):1537–1550. https://pubmed.ncbi.nlm.nih.gov/39530664/
- Yang X, Wang Y, Rovella V, et al. Aged mesenchymal stem cells and inflammation: from pathology to potential therapeutic strategies. Biology Direct. 2023;18:42. https://pubmed.ncbi.nlm.nih.gov/37464416/
- Nguyen NH, Phan HT, Le PM, et al. Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients. Trials. 2024;25:309. https://pmc.ncbi.nlm.nih.gov/articles/PMC11077870/